We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
The Zacks Analyst Blog Highlights ServiceNow, AMD, Sanofi, Team and United-Guardian
Chicago, IL – December 24, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: ServiceNow, Inc. NOW, Advanced Micro Devices, Inc. AMD, Sanofi SNY, Team, Inc. TISI and United-Guardian, Inc. UG.
Here are highlights from Monday’s Analyst Blog:
Top Research Reports for ServiceNow, AMD and Sanofi
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including ServiceNow, Inc. (NOW), Advanced Micro Devices, Inc. (AMD) and Sanofi (SNY), as well as two micro-cap stocks Team, Inc. (TISI) and United-Guardian, Inc. (UG). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
ServiceNow's shares have outperformed the Zacks Computers - IT Services industry over the past year (+56.5% vs. +16.0%). The company has been benefiting from the rising adoption of its workflows by enterprises undergoing digital transformation.
It had 2020 total customers with more than $1 million in annual contract value (ACV) at the end of third quarter, which represents 14% year-over-year growth in customers.ServiceNow had 15 deals greater than $5 million in net new ACV and six deals of more than $10 million. It closed 96 deals greater than $1 million net new ACV.
ServiceNow had 44 new Now Assist customers spending more than $1 million in ACV, including six with more than $5 million and two with more than $10 million. It is also riding an expanding partner base. However, NOW is suffering from persistent inflation, stiff competition and a challenging macroeconomic environment.
(You can read the full research report on ServiceNow here >>>)
Shares of AMD have outperformed the Zacks Computer - Integrated Systems industry over the past two years (+84.8% vs. +73.6%). The company is benefiting from portfolio strength and an expanding partner base. Its portfolio strength is noteworthy, with robust data center demand and accretive acquisitions.
AMD expects fourth-quarter 2024 revenues to be $7.5 billion (+/-$300 million). At the mid-point of its revenue guidance, AMD expects revenues to grow 10% sequentially and 22% year over year, driven by strong growth in the data center and the client segment.
Exiting third-quarter 2024, AMD's public cloud instances increased 20% year over year to more than 950, with Microsoft, AWS, Uber and Netflix deploying it at scale. Acquisitions of ZT Systems and Silo AI expands AMD's portfolio. AMD and its partners, including Microsoft, Oracle, DELL, HPE, Lenovo and Supermicro, have instinct platforms in production.
(You can read the full research report on AMD here >>>)
Sanofi's shares have gained +0.9% over the past year against the Zacks Large Cap Pharmaceuticals industry's gain of +4.9%. The company's Dupixent has become the key top-line driver as it enjoys strong demand across all approved indications and geographies. Sanofi possesses a leading vaccine portfolio that drives the top line.
Several new drugs have been launched in the past couple of years that have become significant contributors to Sanofi's top-line growth. Sanofi has also accelerated its mid- and late-stage pipeline this year. It has also been active on the M&A front.
However, generic erosion of Aubagio in all key markets and lower sales from mature products are hurting sales. Other headwinds include the weak performance of diabetes drugs and regular negative pipeline developments.
(You can read the full research report on Sanofi here >>>)
Shares of Team have outperformed the Zacks Building Products - Maintenance Service industry over the past six months (+85.9% vs. -3.4%). This microcap company with market capitalization of $66.92 million demonstrated resilience in third-quarter 2024, with revenue rising 1.96% year over year to $210.8 million, driven by robust demand for Inspection and Heat Treating and steady performance in Mechanical Services.
Operational improvements yielded a $3.2 million operating income, reversing a prior-year loss, while gross margins improved. A significant legal victory vacating a $222 million judgment strengthened financial stability, and investments in advanced technology position the company for growth.
However, high debt, rising interest costs, ongoing net losses, and declining equity reflect financial strain. Litigation risks, stagnant revenue in key segments, and reliance on cost-cutting amid sector volatility further pressure profitability. Team's diversified, high-margin services provide resilience, but substantial challenges remain.
(You can read the full research report on Team here >>>)
United-Guardian's shares have outperformed the Zacks Medical - Products industry over the past year (+31.3% vs. +12.7%). This microcap company with market capitalization of $44.47 million delivered robust financial results in third-quarter 2024, with a 17.2% year-over-year net sales increase, driven by a 68% surge in cosmetic ingredients sales.
Cosmetics now drive profitability, leveraging strong global demand, offsetting declines in other segments and solidifying the company's focus on high-margin products. A resilient balance sheet with $2.4 million in cash, minimal liabilities and a consistent quarterly dividend of 25 cents underscore financial stability. Investment income grew 63.5% year over year to $0.3 million, adding flexibility.
Despite an 11% dip in pharmaceutical sales, recovery efforts aim to stabilize the segment. Geographic and product diversification, supported by stable investment income, ensures resilience, positioning United-Guardian to capitalize on growth opportunities in high-demand markets.
(You can read the full research report on United-Guardian here >>>)
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
